Long-term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis.

Christopher L Bowlus,Paul J Pockros,Andreas E Kremer,Albert Parés,Lisa M Forman,Joost P H Drenth,Stephen D Ryder,Luigi Terracciano,Yuying Jin,Alexander Liberman,Richard Pencek, Uche Iloeje,Leigh MacConell,Pierre Bedossa

Clinical Gastroenterology and Hepatology（2020）

引用 69|浏览61

暂无评分

摘要

A sub-analysis of data from the POISE study demonstrated that long-term OCA treatment in patients with PBC is associated with improvements or stabilization of disease features, including ductular injury, fibrosis, and collagen morphometry features (ClinicalTrials.gov no: NCT01473524 and EudraCT no: 2011-004728-36).

查看译文

关键词

FXR Agonist,Farnesoid X Receptor Agonist,Liver Disease,Hepatic

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要